Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
PRIMARY OBJECTIVES:
I. To estimate the 2-year cumulative incidence of cardiac dysfunction and/or predefined cardiac events in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy and beta blockers, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitor.
II. To develop a model including clinical factors and potential biomarkers to predict risk of cardiac dysfunction and/or predefined cardiac events in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy and beta blockers, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitor.
SECONDARY OBJECTIVES:
I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no prophylaxis reduces the risk of cardiac dysfunction and/or predefined cardiac events in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy.
II. To evaluate if prophylactic carvedilol compared with no prophylaxis results in a longer time to first interruption of trastuzumab-based HER-2 targeted therapy due to either cardiac dysfunction or events.
III. To compare the local and central reads of left ventricular ejection fraction (LVEF) and strain and assess if strain changes can predict drop in ejection fraction.
IV. Assess if strain can be used in the community as a marker of cardiotoxicity.
TERTIARY OBJECTIVES:
I. To evaluate the lle655Val and Alall70Pro single nucleotide polymorphisms (SNPs) of the HER-2 gene as a predictive biomarker of study-defined cardiac dysfunction and/or predefined cardiac events.
II. To evaluate plasma neuregulin-1 at baseline and over study time as a predictive biomarker of study-defined cardiac dysfunction and/or predefined cardiac events.
III. To evaluate the feasibility of local labs performing serial left ventricular strain in an NCTN group setting, with the goal of 75% of patients contributing both a baseline and at least one follow-up strain measurement.
IV. To bank blood for future translational medicine studies such as brain natriuretic peptide (BNP), additional SNPs, and high sensitivity troponin.
OUTLINE: Patients are randomized to 1 of 2 arms. Patients taking beta blocker, ARB, or ACE inhibitor at registration are assigned to Arm III.
ARM I: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol orally (PO) twice daily (BID). Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
ARM II: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
ARM III: Patients undergo observation for up to 108 weeks.
Inclusion Criteria:
Patients must:
Examples of eligible HER-2 targeted therapy:
Trastuzumab or a trastuzumab biosimilar
Trastuzumab + chemotherapy or hormonal therapy
Trastuzumab + other HER-2 targeted agent with or without chemotherapy (such as pertuzumab, lapatinib, and tucatinib)
Ado-trastuzumab (Kadcyla®)
Fam-trastuzumab deruxtecan (Enhertu) NOTE: Patients on lapatinib without trastuzumab are not eligible. Planned treatment with concurrent HER-2 targeted therapy and anthracyclines is not permitted.
Patients must be at increased risk for cardiotoxicity defined by at least one of the following:
Previous anthracycline exposure OR
1 or more of the following risk factors for heart disease:
Patients must not have taken within 21 days prior to Step 1 Registration, be currently taking at the time of Step 1 Registration or planning to take once registered to Step 1 a beta blocker, ARB, or ACE inhibitor, in order to be randomized (Arms 1 and 2).
Patients enrolling in the observational cohort (Arm 3) must be currently taking a beta blocker, ARB, or ACE inhibitor at the time of Step 1 Registration.
If a 3D echocardiogram is performed at baseline, sites must ensure that standard 2D images, including 40chamber and 2-chamber views, are also obtained and submitted at subsequent timepoints.
All follow-up echocardiograms (every 12 weeks) must be performed using 2D imaging to allow for standardized assessments. Follow-up scans must be completed at a site that can provide 2D images per protocol requirements. The echocardiograms cannot be submitted for central read until after Step 1 registration is complete.
Patients must have adequate hepatic function as evidenced by all of the following within 28 days prior to registration:
Patients must not be dialysis dependent
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer on active surveillance, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
Patients must not be pregnant or nursing due to potential fetal or nursing infant harm; women/men of reproductive potential must have agreed to use an effective contraceptive method, a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
Patients must be willing to submit blood specimens
Sites must seek additional patient consent for the future use of specimens
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and CIRB regulations.
As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
STEP 2 REGISTRATION (Randomization)
Patients must not be registered to step 2 until confirming via RAVE EDC that the patient's LVEF by echocardiogram was >= 50% by central review. Patients must be registered within 21 calendar days of submission of the ECHO study/
Site must verify that there is no known change in the step 1 eligibility since initial registration
Antioch, California 94531, United States
Burbank, California 91505, United States
Oakland, California 94609, United States
Rancho Cordova, California 95670, United States
Roseville, California 95678, United States
Sacramento, California 95817, United States
San Jose, California 95119, United States
Santa Clara, California 95051, United States
South San Francisco, California 94080, United States
South San Francisco, California 94080, United States
Vacaville, California 95688, United States
Stamford, Connecticut 06904, United States
Savannah, Georgia 31405, United States
Honolulu, Hawaii 96819, United States
Pekin, Illinois 61554, United States
Peoria, Illinois 61615, United States
Clive, Iowa 50325, United States
Des Moines, Iowa 50309, United States
Lenexa, Kansas 66219, United States
Overland Park, Kansas 66210, United States
Overland Park, Kansas 66211, United States
Topeka, Kansas 66606, United States
Baton Rouge, Louisiana 70809, United States
Covington, Louisiana 70433, United States
Shreveport, Louisiana 71103, United States
Ann Arbor, Michigan 48109, United States
Brighton, Michigan 48114, United States
Brownstown, Michigan 48183, United States
CTOResearch@hfhs.org313-916-3721
Canton, Michigan 48188, United States
Chelsea, Michigan 48118, United States
Clinton Township, Michigan 48038, United States
East China Township, Michigan 48054, United States
Grosse Pointe Woods, Michigan 48236, United States
Grosse Pointe Woods, Michigan 48236, United States
Lansing, Michigan 48910, United States
Macomb, Michigan 48044, United States
Marlette, Michigan 48453, United States
Rochester Hills, Michigan 48309, United States
Warren, Michigan 48093, United States
West Branch, Michigan 48661, United States
Ypsilanti, Michigan 48197, United States
Brainerd, Minnesota 56401, United States
Duluth, Minnesota 55805, United States
Fergus Falls, Minnesota 56537, United States
Columbus, Mississippi 39705, United States
New Albany, Mississippi 38652, United States
Southhaven, Mississippi 38671, United States
City of Saint Peters, Missouri 63376, United States
Creve Coeur, Missouri 63141, United States
Kansas City, Missouri 64111, United States
Lee's Summit, Missouri 64064, United States
North Kansas City, Missouri 64116, United States
St Louis, Missouri 63110, United States
St Louis, Missouri 63136, United States
Somerville, New Jersey 08876, United States
New York, New York 10032, United States
Stony Brook, New York 11794, United States
Clinton, North Carolina 28328, United States
Goldsboro, North Carolina 27534, United States
Jacksonville, North Carolina 28546, United States
Fargo, North Dakota 58103, United States
Centerville, Ohio 45459, United States
Cincinnati, Ohio 45219, United States
Dayton, Ohio 45415, United States
Franklin, Ohio 45005-1066, United States
Middleburg Heights, Ohio 44130, United States
West Chester, Ohio 45069, United States
Wooster, Ohio 44691, United States
Oklahoma City, Oklahoma 73104, United States
Tulsa, Oklahoma 74146, United States
Chadds Ford, Pennsylvania 19317, United States
Boiling Springs, South Carolina 29316, United States
Charleston, South Carolina 29425, United States
Sioux Falls, South Dakota 57104, United States
Sioux Falls, South Dakota 57117-5134, United States
Collierville, Tennessee 38017, United States
Memphis, Tennessee 38120, United States
San Antonio, Texas 78229, United States
Fishersville, Virginia 22939, United States
Bainbridge Island, Washington 98110, United States
Bremerton, Washington 98310, United States
Federal Way, Washington 98002, United States
Gig Harbor, Washington 98332, United States
Lynnwood, Washington 98036, United States
Poulsbo, Washington 98370, United States
Puyallup, Washington 98372, United States
Seattle, Washington 98195, United States
Spokane, Washington 99204, United States
Spokane, Washington 99218, United States
Spokane Valley, Washington 99216, United States
Tacoma, Washington 97405, United States
Tacoma, Washington 98405, United States
Yakima, Washington 98902, United States
Janesville, Wisconsin 53548, United States
Riyadh, 11211, Saudi Arabia
becomingapatient@coh.org800-826-4673
323-865-0451
925-957-5400
becomingapatient@coh.org800-826-4673
877-467-3411
becomingapatient@coh.org800-826-4673
877-467-3411
becomingapatient@coh.org800-826-4673
mary_ella_quillen@bayhealth.org302-744-6755
research@beebehealthcare.org302-291-6730
research@beebehealthcare.org302-291-6730
ClinicalTrials@moffitt.org800-679-0775
CancerAnswer@ccf.org954-659-5705
404-778-1868
ClinicalTrials@northside.com404-303-3355
cancerpatient.navigator@nghs.com770-219-8800
underberga@sjchs.org912-819-5704
ctsucontact@westat.com888-823-5923
stephanie.couch@stjoeshealth.org734-712-3671
mccinfo@mtcancer.org406-969-6060
312-864-5204
morganthaler.jodi@mhsil.com217-876-4762
708-226-4357
morganthaler.jodi@mhsil.com217-876-4762
317-528-7060
ctsucontact@westat.com888-823-5923
317-834-3603
515-241-3305
cancerresearch@mercydesmoines.org515-358-6613
cancerresearch@mercydesmoines.org515-358-6613
515-241-3305
cancerresearch@mercydesmoines.org515-358-6613
785-623-5774
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
Jeni.wakefield@olathehealth.org913-355-8000
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
785-295-8000
KUCC_Navigation@kumc.edu913-588-3671
ResearchInstituteInquiries@CommonSpirit.org859-629-7169
research@ololrmc.com225-765-7659
clinicalresearch@marybird.com225-215-1353
clinicalresearch@marybird.com225-215-1353
research@ololrmc.com225-765-7659
clinicalresearch@marybird.com225-215-1353
research@ololrmc.com225-765-7659
Clinicalreserach@marybird.com225-215-1353
443-643-3010
lhmc-cancer-clinical-trials@lahey.org781-744-3421
protocols@swog.org
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
800-865-1125
ctoadmin@karmanos.org313-576-9790
ctoadmin@karmanos.org313-576-9790
CTOResearch@hfhs.org313-916-3721
CTOResearch@hfhs.org313-916-3721
ctoadmin@karmanos.org313-576-9790
CTOResearch@hfhs.org313-916-3721
ctoadmin@karmanos.org313-576-9790
ctoadmin@karmanos.org313-576-9790
crcwm-regulatory@crcwm.org616-391-1230
ctoadmin@karmanos.org313-576-9790
ctoadmin@karmanos.org313-576-9790
ctoadmin@karmanos.org313-576-9790
CTOResearch@hfhs.org313-916-3721
karen.fife@ascension.org248-849-5332
CTOResearch@hfhs.org313-916-3721
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
BCCclintrials@bmhcc.org901-226-1366
601-815-6700
314-251-7058
sfmc@sfmc.net573-334-2230
swooden@mail.crmc.org573-632-4814
816-404-4375
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
KUCC_Navigation@kumc.edu913-588-3671
417-269-4520
417-269-4520
314-353-1870
janet.lesko@mercy.net
314-996-5569
314-251-7066
mccinfo@mtcancer.org406-969-6060
973-971-5900
908-522-2043
201-833-6312
HSC-ClinicalTrialInfo@salud.unm.edu505-925-0348
845-348-8507
mcortese@wphospital.org914-849-7582
CancerAnswer@ccf.org866-223-8100
CTUReferral@UHhospitals.org800-641-2422
ClinicalReserachDept@aultman.com330-363-7274
CTUReferral@UHhospitals.org800-641-2422
513-585-0844
cancer@uchealth.com513-584-7698
CTUReferral@UHhospitals.org800-641-2422
TaussigResearch@ccf.org866-223-8100
TaussigResearch@ccf.org866-223-8100
TaussigResearch@ccf.org866-223-8100
TaussigResearch@ccf.org866-223-8100
TaussigResearch@ccf.org866-223-8100
TaussigResearch@ccf.org866-223-8100
TaussigResearch@ccf.org866-223-8100
CTUReferral@UHhospitals.org800-641-2422
TaussigResearch@ccf.org866-223-8100
cancer@uchealth.com513-584-7698
CTUReferral@UHhospitals.org800-641-2422
CTUReferral@UHhospitals.org800-641-2422
TaussigResearch@ccf.org866-223-8100
information@kpchr.org503-335-2400
trials@ohsu.edu503-494-1080
Morgan_M.Horton@lvhn.org610-402-9543
Morgan_M.Horton@lvhn.org610-402-9543
CTO@hmc.psu.edu717-531-3779
800-836-0388
864-241-6251
864-241-6251
864-241-6251
BCCclintrials@bmhcc.org901-226-1366
canceranswerline@UTSouthwestern.edu214-648-7097
canceranswerline@UTSouthwestern.edu214-648-7097
Suzanne.cole@utsouthwestern.edu972-669-7044
540-332-5960
360-788-8223
PCRC-NCORP@Swedish.org206-215-3086
800-804-8824
PCRC-NCORP@Swedish.org206-215-3086
800-804-8824
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
cancertrialsinfo@hsc.wvu.edu304-293-7374
304-243-6442
82-31-920-1934